# Dextroamphetamine
*Source: https://go.drugbank.com/drugs/DB01576*

## Overview

### Description

This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.

### Background

Dextroamphetamine is the dextrorotatory enantiomer of amphetamine
5
. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.
6
,
8

### Indication

Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD)
7
,
8
and narcolepsy.
8

### Pharmacodynamics

Dextroamphetamine is a noncatecholamine, sympathomimetic amine that acts as a CNS stimulant.
7
Dextroamphetamine raises systolic and diastolic blood pressure, acts as a weak bronchodilator, and also acts as a respiratory stimulant.
7
The general mechanism of action of dextroamphetamine has not been well established.
7

### Mechanism of Action

Synaptic vesicular amine transporter
Inducer
Sodium-dependent noradrenaline transporter
Negative modulator
Sodium-dependent dopamine transporter
Negative modulator

### Absorption

Bioavailability data of dextroamphetamine is not readily available, however there is no difference in bioavailability when taken with or without a meal.
8

### Metabolism

Dextroamphetamine is metabolized by cytochrome P-450 2D6 in the liver to 4-hydroxyamphetamine and later conjugated by sulfotransferase or glucoronyltransferase.
1
Hover over products below to view reaction partners
Dextroamphetamine
4-hydroxyamphetamine

### Half-life

11.75 hours.
8
In a study of post-stroke patients the half life was 16.0 hours in females and 12.4 hours in males.
5
Studies in healthy populations show a half life of 7.9 hours.
3

### Toxicity

Dextroamphetamine has been shown to be teratogenic and embryotoxic in mice at 41 times the maximum human dose.
8
These effects were not seen in rat or rabbit studies, and the effects on human pregnancy have not been studied.
8
The risk and benefit of use during pregnancy should be weighed as bone deformities, tracheoesophageal fistula, anal atresia, low birthweight, and withdrawl have been reported in the children of mothers who were taking dextroamphetamine during pregnancy.
8
Mothers should not take amphetamines while nursing as the drug is excreted in breast milk.
8
Long term effects of dextroamphetamine have not bee determined in pediatric patients and dextroamphetamine should be avoided in children under 3 years.
8

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Abatacept
The metabolism of Dextroamphetamine can be increased when combined with Abatacept.
Abiraterone
The metabolism of Dextroamphetamine can be decreased when combined with Abiraterone.
Acebutolol
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Dextroamphetamine.
Aceclofenac
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Aceclofenac.
Acemetacin
The risk or severity of hypertension can be increased when Dextroamphetamine is combined with Acemetacin.

### Food Interactions

Avoid fruit juice. Fruit juice may acidify the gastrointestinal tract, decreasing absorption of amphetamines.

## Chemical Information

**DrugBank ID:** DB01576

**Synonyms:** (+)-(S)-amphetamine
(+)-amphetamine
(+)-α-methylphenethylamine
(+)-α-methylphenylethylamine
(S)-(+)-amphetamine
(S)-(+)-β-phenylisopropylamine
(S)-1-phenyl-2-aminopropane
(S)-1-phenyl-2-propylamine
(S)-amphetamine
(S)-α-methylbenzeneethanamine
(αS)-α-methylbenzeneethanamine
d-amphetamine
Desamfetamina
Dexamfetamina
Dexamfetamine
Dexamfetaminum
Dexamphetamine
Dexanfetamina
Dextroamphetamine

**Chemical Formula:** C
9
H
13
N

**SMILES:** C[C@H](N)CC1=CC=CC=C1

**Weight:** Average: 135.2062
Monoisotopic: 135.104799421

**IUPAC Name:** (2S)-1-phenylpropan-2-amine

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US6384020
Yes
2002-05-07
2021-01-06
US
USRE42096
Yes
2011-02-01
2019-04-21
US
US6605300
Yes
2003-08-12
2019-04-21
US
US6322819
Yes
2001-11-27
2019-04-21
US
USRE41148
Yes
2010-02-23
2019-04-21
US
US8632802
No
2014-01-21
2025-10-07
US
US9034370
No
2015-05-19
2025-10-07
US
US9173857
No
2015-11-03
2026-05-12
US
US6913768
No
2005-07-05
2023-05-24
US
US8846100
No
2014-09-30
2029-08-24
US
US9456993
No
2016-10-04
2033-10-24
US
US9474722
No
2016-10-25
2033-10-24
US
US8591941
No
2013-11-26
2025-10-07
US
US11559501
No
2023-01-24
2042-01-06
US

### Indicated Conditions

2

### Phase 0

4

### Phase 1

10

### Phase 2

24

### Phase 3

3

### Phase 4

19

### Therapeutic Categories

Amphetamines
Central Nervous System
Stimulants

### Summary

Dextroamphetamine
is a sympathomimetic agent used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.

### Brand Names

Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi

### Generic Name

Dextroamphetamine

### DrugBank Accession Number

DB01576

### Groups

Approved, Illicit, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Dextroamphetamine (DB01576)
×
Close

### External IDs

NSC-73713

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
•••••
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
••••••••••
Used in combination to manage
Attention deficit hyperactivity disorder
Combination Product in combination with:
Amphetamine (DB00182)
••••••••••••
Create Account
••••••••
Management of
Attention deficit hyperactivity disorder
••••••••••••
Create Account
Management of
Narcolepsy
••••••••••••
Create Account
Create Account

### Mechanism of action

The exact mechanism of amphetamines as a class is not known. Dextroamphetamine acts by preventing reuptake, increasing release, and stimulating reverse-transport of dopamine in synaptic clefts in the striatum.
4
Newer evidence shows amphetamines may also alter the number of dopamine transporters in synaptic clefts.
2
Target
Actions
Organism
A
Synaptic vesicular amine transporter
inducer
Humans
A
Sodium-dependent noradrenaline transporter
negative modulator
Humans
A
Sodium-dependent dopamine transporter
negative modulator
Humans
U
Trace amine-associated receptor 1
agonist
Humans
U
Alpha-1B adrenergic receptor
antagonist
Humans
U
Alpha adrenergic receptor
inhibitor
inducer
Humans

### Volume of distribution

195L.
3

### Route of elimination

A third of the drug is eliminated renally.
5

### Clearance

17L/h.
3

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Dextroamphetamine adipate
YYI1A8W4TQ
64770-52-1
OFCJKOOVFDGTLY-QRPNPIFTSA-N
Dextroamphetamine saccharate
G83415V073
350708-40-6
CXFNVDBOUVJOQO-OUDZKKFGSA-N
Dextroamphetamine sulfate
JJ768O327N
51-63-8
SOFQDLYSFOWTJX-QRPNPIFTSA-N

### Product Images

Previous
Next

### International/Other Brands

Attentin (Medice)
/
Dexamphetamine (Sigma)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Adderall XR
Capsule, extended release
6.25 mg
Oral
Takeda Italia S.P.A.
2004-01-30
Not applicable
Canada
Adderall XR
Capsule, extended release
6.25 mg
Oral
Takeda Italia S.P.A.
2004-01-30
Not applicable
Canada
Dexedrine
Tablet
5 mg
Oral
Endo Operations Ltd.
1992-12-31
Not applicable
Canada
Dexedrine
Capsule, extended release
5 mg/1
Oral
Glaxosmithkline Inc
2007-11-14
2012-05-31
US
Dexedrine
Tablet
5 mg/1
Oral
Glaxosmithkline Inc
2007-04-10
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Apo-dextroamphetamine SR
Capsule, extended release
15 mg
Oral
Apotex Corporation
Not applicable
Not applicable
Canada
Apo-dextroamphetamine SR
Capsule, extended release
10 mg
Oral
Apotex Corporation
Not applicable
Not applicable
Canada
Dexedrine
Tablet
10 mg/1
Oral
Amedra Pharmaceuticals LLC
2014-07-01
2016-09-30
US
Dexedrine
Tablet
5 mg/1
Oral
Physicians Total Care, Inc.
2004-12-16
2011-05-31
US
Dexedrine
Tablet
5 mg/1
Oral
Amedra Pharmaceuticals LLC
2014-07-01
2016-09-30
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Adderall
Dextroamphetamine saccharate
(5 mg/1)
+
Dextroamphetamine sulfate
(5 mg/1)
+
Amphetamine aspartate
(5 mg/1)
+
Amphetamine sulfate
(5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(5 mg/1)
+
Dextroamphetamine sulfate
(5 mg/1)
+
Amphetamine aspartate
(5 mg/1)
+
Amphetamine sulfate
(5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(2.5 mg/1)
+
Dextroamphetamine sulfate
(2.5 mg/1)
+
Amphetamine aspartate
(2.5 mg/1)
+
Amphetamine sulfate
(2.5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(2.5 mg/1)
+
Dextroamphetamine sulfate
(2.5 mg/1)
+
Amphetamine aspartate
(2.5 mg/1)
+
Amphetamine sulfate
(2.5 mg/1)
Tablet
Oral
bryant ranch prepack
1996-02-13
Not applicable
US
Adderall
Dextroamphetamine saccharate
(1.25 mg/1)
+
Dextroamphetamine sulfate
(1.25 mg/1)
+
Amphetamine aspartate
(1.25 mg/1)
+
Amphetamine sulfate
(1.25 mg/1)
Tablet
Oral
Physicians Total Care, Inc.
1997-10-02
2011-07-31
US

### ATC Codes

N06BA02 — Dexamfetamine
N06BA — Centrally acting sympathomimetics
N06B — PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06 — PSYCHOANALEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Agents producing tachycardia
Agents that produce hypertension
Amines
Amphetamines
Central Nervous System Agents
Central Nervous System Stimulants
Central Nervous System Stimulation
Centrally Acting Sympathomimetics
Cytochrome P-450 CYP2D6 Substrates
Cytochrome P-450 Substrates
Dopamine Agents
Dopamine Uptake Inhibitors
Ethylamines
Membrane Transport Modulators
Nervous System
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Phenethylamines
Psychoanaleptics
Psychostimulants, Agents Used for ADHD and Nootropics
Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
Sympathomimetics

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenethylamines
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes
/
Aralkylamines
/
Organopnictogen compounds
/
Monoalkylamines
/
Hydrocarbon derivatives
Substituents
Amine
/
Amphetamine or derivatives
/
Aralkylamine
/
Aromatic homomonocyclic compound
/
Hydrocarbon derivative
/
Organic nitrogen compound
/
Organonitrogen compound
/
Organopnictogen compound
/
Phenylpropane
/
Primary aliphatic amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamine (
CHEBI:4469
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Phenethylamines

### Direct Parent

Amphetamines and derivatives

### Alternative Parents

Phenylpropanes
/
Aralkylamines
/
Organopnictogen compounds
/
Monoalkylamines
/
Hydrocarbon derivatives

### Substituents

Amine
/
Amphetamine or derivatives
/
Aralkylamine
/
Aromatic homomonocyclic compound
/
Hydrocarbon derivative
/
Organic nitrogen compound
/
Organonitrogen compound
/
Organopnictogen compound
/
Phenylpropane
/
Primary aliphatic amine

### Molecular Framework

Aromatic homomonocyclic compounds

### External Descriptors

amphetamine (
CHEBI:4469
)

### Affected organisms

Humans and other mammals

### UNII

TZ47U051FI

### CAS number

51-64-9

### InChI Key

KWTSXDURSIMDCE-QMMMGPOBSA-N

### InChI

InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

### Synthesis Reference

Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French
Laboratories.

### General References

de la Torre R, Farre M, Navarro M, Pacifici R, Zuccaro P, Pichini S: Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002. [
Article
]
Saunders C, Galli A: Insights in how amphetamine ROCKs (Rho-associated containing kinase) membrane protein trafficking. Proc Natl Acad Sci U S A. 2015 Dec 22;112(51):15538-9. doi: 10.1073/pnas.1520960112. Epub 2015 Nov 25. [
Article
]
Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME: Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front Pharmacol. 2017 Sep 7;8:617. doi: 10.3389/fphar.2017.00617. eCollection 2017. [
Article
]
Calipari ES, Ferris MJ: Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013 May 22;33(21):8923-5. doi: 10.1523/JNEUROSCI.1033-13.2013. [
Article
]
Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. [
Article
]
FDA Drug Approval Package for Dextroamphetamine [
Link
]
FDA Approved Drug Products: Adderall (dextroamphetamine) capsule [
Link
]
FDA Approved Drug Products: DEXEDRINE (dextroamphetamine sulfate) SPANSULE® sustained-release capsules, CII [
Link
]

### External Links

Human Metabolome Database
HMDB0015516
KEGG Drug
D03740
KEGG Compound
C07884
PubChem Compound
5826
PubChem Substance
46506252
ChemSpider
5621
BindingDB
50022723
RxNav
3288
ChEBI
4469
ChEMBL
CHEMBL612
ZINC
ZINC000006021033
Therapeutic Targets Database
DAP001470
PharmGKB
PA448408
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
1WE
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dextroamphetamine

### Human Metabolome Database

HMDB0015516

### KEGG Drug

D03740

### KEGG Compound

C07884

### PubChem Compound

5826

### PubChem Substance

46506252

### ChemSpider

5621

### BindingDB

50022723

### RxNav

3288

### ChEBI

4469

### ChEMBL

CHEMBL612

### ZINC

ZINC000006021033

### Therapeutic Targets Database

DAP001470

### PharmGKB

PA448408

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

1WE

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Dextroamphetamine

### PDB Entries

4lar
/
4xp9
/
8jso
/
8tgh
/
8uco

### MSDS

Download
(145 KB)

### Packagers

Abbott Laboratories Ltd.
Actavis Group
Auriga Pharmaceuticals LLC
Barr Pharmaceuticals
Bryant Ranch Prepack
Cardinal Health
Catalent Pharma Solutions
Corepharma LLC
D.M. Graham Laboratories Inc.
Dispensing Solutions
DSM Corp.
Eon Labs
Ethex Corp.
GlaxoSmithKline Inc.
Global Pharmaceuticals
Lundbeck Inc.
Mallinckrodt Inc.
Mikart Inc.
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Professional Co.
Ranbaxy Laboratories
Shire Inc.
Stat Rx Usa
Tiber Pharmaceuticals LLC

### Dosage Forms

Form
Route
Strength
Capsule, extended release
Oral
6.25 mg
Capsule, extended release
Oral
10 mg/1
Capsule, extended release
Oral
15 mg/1
Capsule, extended release
Oral
5 mg/1
Tablet
Oral
5 mg
Tablet
Oral
5 mg/1
Capsule, extended release
Oral
10 mg
Capsule, extended release
Oral
15 mg
Capsule
Oral
Capsule, extended release
Oral
Tablet
Oral
Solution
Oral
5 mg/5mL
Tablet
Oral
10 mg/1
Liquid
Oral
5 mg/5mL
Patch, extended release
Topical
13.5 mg/1
Patch, extended release
Topical
18 mg/1
Patch, extended release
Topical
4.5 mg/1
Patch, extended release
Topical
9 mg/1
Tablet
Oral
15 mg/1
Tablet
Oral
2.5 mg/1
Tablet
Oral
20 mg/1
Tablet
Oral
30 mg/1
Tablet
Oral
7.5 mg/1

### Prices

Unit description
Cost
Unit
D-amphetamine sulfate powder
900.0USD
g
Desoxyn 5 mg tablet
5.1USD
tablet
Dexedrine 15 mg 24 Hour Capsule
4.22USD
capsule
Dextroamphetamine Sulfate CR 15 mg 24 Hour Capsule
3.47USD
capsule
Dexedrine 10 mg 24 Hour Capsule
3.23USD
capsule
Dexedrine 5 mg 24 Hour Capsule
3.0USD
capsule
Dextroamphetamine Sulfate CR 10 mg 24 Hour Capsule
2.96USD
capsule
Dexedrine spansule 15 mg
2.45USD
each
Dextroamphetamine Sulfate CR 5 mg 24 Hour Capsule
2.06USD
capsule
Dexedrine spansule 10 mg
1.91USD
each
Dexedrine spansule 5 mg
1.91USD
each
Dexedrine 15 mg Sustained-Release Capsule
1.08USD
capsule
Dextroamphetamine Sulfate 10 mg tablet
0.92USD
tablet
Dexedrine 10 mg Sustained-Release Capsule
0.89USD
capsule
Dextroamphetamine Sulfate 5 mg tablet
0.65USD
tablet
Dexedrine 5 mg Tablet
0.62USD
tablet
Dextroamphetamine 10 mg tablet
0.56USD
tablet
Dextrostat 10 mg tablet
0.48USD
tablet
Dextroamphetamine 5 mg tablet
0.28USD
tablet
Dextrostat 5 mg tablet
0.25USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Liquid

### Experimental Properties

Property
Value
Source
melting point (°C)
-98
[MSDS]
boiling point (°C)
64.7
[MSDS]
water solubility
Moderately Soluble
[MSDS]

### Predicted Properties

Property
Value
Source
Water Solubility
1.74 mg/mL
ALOGPS
logP
1.85
ALOGPS
logP
1.8
Chemaxon
logS
-1.9
ALOGPS
pKa (Strongest Basic)
10.01
Chemaxon
Physiological Charge
1
Chemaxon
Hydrogen Acceptor Count
1
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
26.02 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
43.71 m
3
·mol
-1
Chemaxon
Polarizability
16.08 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
No
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9972
Blood Brain Barrier
+
0.9565
Caco-2 permeable
+
0.8395
P-glycoprotein substrate
Non-substrate
0.7379
P-glycoprotein inhibitor I
Non-inhibitor
0.9519
P-glycoprotein inhibitor II
Non-inhibitor
0.9859
Renal organic cation transporter
Non-inhibitor
0.8002
CYP450 2C9 substrate
Non-substrate
0.8114
CYP450 2D6 substrate
Substrate
0.8919
CYP450 3A4 substrate
Non-substrate
0.795
CYP450 1A2 substrate
Non-inhibitor
0.5697
CYP450 2C9 inhibitor
Non-inhibitor
0.9313
CYP450 2D6 inhibitor
Inhibitor
0.657
CYP450 2C19 inhibitor
Non-inhibitor
0.8445
CYP450 3A4 inhibitor
Non-inhibitor
0.8709
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.8732
Ames test
Non AMES toxic
0.93
Carcinogenicity
Non-carcinogens
0.6869
Biodegradation
Not ready biodegradable
0.6575
Rat acute toxicity
3.2491 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9452
hERG inhibition (predictor II)
Non-inhibitor
0.9231
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(6.85 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0006-9100000000-41224b447ebed58b4d86
Mass Spectrum (Electron Ionization)
MS
splash10-0006-9000000000-f40d32a5bced4783345a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00kf-9500000000-5b99f81fa83e55e904bc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-015c-2900000000-6b67a9199ff61ba7506b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-9400000000-6052d3a0dac0780497c5
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9300000000-44c12c2637a4565bf91a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-037fb8f36c878115fcc5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-c70e8a43d2a9c0d44a49
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
130.813261
predicted
DarkChem Lite v0.1.0
[M-H]-
129.93782
predicted
DeepCCS 1.0 (2019)
[M+H]+
131.854361
predicted
DarkChem Lite v0.1.0
[M+H]+
133.15218
predicted
DeepCCS 1.0 (2019)
[M+Na]+
131.248361
predicted
DarkChem Lite v0.1.0
[M+Na]+
142.44734
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

Mediates sodium- and chloride-dependent transport of dopamine (PubMed:10375632, PubMed:11093780, PubMed:1406597, PubMed:15505207, PubMed:19478460, PubMed:39112701, PubMed:39112703, PubMed:39112705, PubMed:8302271). Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

### Specific Function

amine binding

### Gene Name

SLC6A3

### Uniprot ID

Q01959

### Uniprot Name

Sodium-dependent dopamine transporter

### Molecular Weight

68494.255 Da

### Curator comments

There are limited data in the literature to support this target action. Adrenergic receptors are possible targets for dextroamphetamine based on indirect evidence.

